Mass Device sister publication Drug Delivery Business News reported recently that Clearside Bio, a GCMI client, “has enrolled the first patient in a Phase III trial evaluating its eye drug combined with an intravitreally-administered anti-VEGF agent as a treatment for macular edema associated with retinal vein occlusion.”
Reporter Sarah Faulkner goes on to write, “The company’s drug, CLS-TA, is a proprietary suspension of triamcinolone acetonide designed to be administered in the space located between the choroid and the sclera.
“Clearside’s Ph3 Topaz trial will evaluate the drug’s safety and efficacy when given with one of two intravitreal anti-VEGF agents: Roche’s Lucentis or Genentech’s Avastin. The late-stage trial is slated to enroll 460 patients, according to Clearside.”
You can read the article in its entirety here.
GCMI was proud to support Clearside Bio in the early development and prototyping of critical elements for the company’s combination products intended to treat blinding diseases of the eye.
“GCMI was instrumental in our early development including prototyping that led to a product candidate we could take into clinical trials,” said Rafael Andino, vice president of engineering and manufacturing for Clearside Bio. “We used their space, cleanrooms, equipment and personnel to help develop and validate our product candidate and its value.”
The product candidates produced by Clearside paired with their novel, proprietary microinjector have the potential to provide therapy to millions of people worldwide. Read more about how they are making it happen and what innovators can learn from their experience.
Are you a physician, engineer or startup with an idea for a new piece of medical technology? Contact GCMI today to connect with experts across the medical device ecosystem who can provide the guidance you need to advance your product’s journey from concept through commercialization.